| Different dysregulations of CYFIP1 and CYFIP2 in distinct types of dementia. | Different dysregulations of CYFIP1 and CYFIP2 in distinct types of dementia.
Peng X, Wellard N, Ghosh A, Troakes C, Giese KP. | 01/17/2024 |
| CYFIP2 serves as a prognostic biomarker and correlates with tumor immune microenvironment in human cancers. | CYFIP2 serves as a prognostic biomarker and correlates with tumor immune microenvironment in human cancers.
Peng Q, Ren B, Xin K, Liu W, Alam MS, Yang Y, Gu X, Zhu Y, Tian Y., Free PMC Article | 09/27/2023 |
| Molecular Dynamics of CYFIP2 Protein and Its R87C Variant Related to Early Infantile Epileptic Encephalopathy. | Molecular Dynamics of CYFIP2 Protein and Its R87C Variant Related to Early Infantile Epileptic Encephalopathy.
Biembengut ÍV, Shigunov P, Frota NF, Lourenzoni MR, de Souza TACB., Free PMC Article | 08/27/2022 |
| Cytoplasmic FMR1 interacting protein (CYFIP) family members and their function in neural development and disorders. | Cytoplasmic FMR1 interacting protein (CYFIP) family members and their function in neural development and disorders.
Biembengut ÍV, Silva ILZ, Souza TACB, Shigunov P. | 01/29/2022 |
| NUAK2 silencing inhibits the proliferation, migration and epithelialtomesenchymal transition of cervical cancer cells via upregulating CYFIP2. | NUAK2 silencing inhibits the proliferation, migration and epithelial‑to‑mesenchymal transition of cervical cancer cells via upregulating CYFIP2.
Li Y, Song X, Liu L, Yue L., Free PMC Article | 01/22/2022 |
| New insights into the clinical and molecular spectrum of the novel CYFIP2-related neurodevelopmental disorder and impairment of the WRC-mediated actin dynamics. | New insights into the clinical and molecular spectrum of the novel CYFIP2-related neurodevelopmental disorder and impairment of the WRC-mediated actin dynamics.
Begemann A, Sticht H, Begtrup A, Vitobello A, Faivre L, Banka S, Alhaddad B, Asadollahi R, Becker J, Bierhals T, Brown KE, Bruel AL, Brunet T, Carneiro M, Cremer K, Day R, Denommé-Pichon AS, Dyment DA, Engels H, Fisher R, Goh ES, Hajianpour MJ, Haertel LRM, Hauer N, Hempel M, Herget T, Johannsen J, Kraus C, Le Guyader G, Lesca G, Mau-Them FT, McDermott JH, McWalter K, Meyer P, Õunap K, Popp B, Reimand T, Riedhammer KM, Russo M, Sadleir LG, Saenz M, Schiff M, Schuler E, Syrbe S, Van der Ven AT, Verloes A, Willems M, Zweier C, Steindl K, Zweier M, Rauch A., Free PMC Article | 07/10/2021 |
| This study evidenced a variety of de novo variants in CYFIP2 as a novel cause of mostly severe intellectual disability with seizures and muscular hypotonia. | Spatially clustering de novo variants in CYFIP2, encoding the cytoplasmic FMRP interacting protein 2, cause intellectual disability and seizures.
Zweier M, Begemann A, McWalter K, Cho MT, Abela L, Banka S, Behring B, Berger A, Brown CW, Carneiro M, Chen J, Cooper GM, Deciphering Developmental Disorders (DDD) Study, Finnila CR, Guillen Sacoto MJ, Henderson A, Hüffmeier U, Joset P, Kerr B, Lesca G, Leszinski GS, McDermott JH, Meltzer MR, Monaghan KG, Mostafavi R, Õunap K, Plecko B, Powis Z, Purcarin G, Reimand T, Riedhammer KM, Schreiber JM, Sirsi D, Wierenga KJ, Wojcik MH, Papuc SM, Steindl K, Sticht H, Rauch A., Free PMC Article | 06/13/2020 |
| The importance of the ATRX/DAXX pathway was confirmed by the first-ever pancreatic neuroendocrine neoplasms (pNEN)-specific protein-damaging hotspot mutation in DAXX. In this study, both novel genes, including the pro-apoptotic CYFIP2 gene and hedgehog signaling PTCH2, and novel pathways, such as the MAPK-ERK pathway, were implicated in pNEN. | Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.
Vandamme T, Beyens M, Boons G, Schepers A, Kamp K, Biermann K, Pauwels P, De Herder WW, Hofland LJ, Peeters M, Van Camp G, Op de Beeck K. | 03/7/2020 |
| This study identified de novo CYFIP2 variants at the Arg87 residue in cause early-onset epileptic encephalopathy. | De novo hotspot variants in CYFIP2 cause early-onset epileptic encephalopathy.
Nakashima M, Kato M, Aoto K, Shiina M, Belal H, Mukaida S, Kumada S, Sato A, Zerem A, Lerman-Sagie T, Lev D, Leong HY, Tsurusaki Y, Mizuguchi T, Miyatake S, Miyake N, Ogata K, Saitsu H, Matsumoto N. | 08/3/2019 |
| The current study provides further supports for contribution of CYFIP1/2 in the pathogenesis of autism spectrum disorder (ASD) and potentiates it as a peripheral marker for ASD diagnosis. | Cytoplasmic FMRP interacting protein 1/2 (CYFIP1/2) expression analysis in autism.
Noroozi R, Omrani MD, Sayad A, Taheri M, Ghafouri-Fard S. | 07/27/2019 |
| Study characterized the functional roles of the two brain-specific phosphorylation sites (S582 and T1067) of CYFIP2 in cultured hippocampal neurons; found that overexpression of the phospho-blocking T1067A mutant significantly decreased the density of stubby spines, but not other types of spines. Study found that T1067 phosphorylation of CYFIP2 could potentially weaken the interaction between CYFIP2 and Nap1. | Phosphorylation of CYFIP2, a component of the WAVE-regulatory complex, regulates dendritic spine density and neurite outgrowth in cultured hippocampal neurons potentially by affecting the complex assembly.
Lee Y, Kim D, Ryu JR, Zhang Y, Kim S, Kim Y, Lee B, Sun W, Han K. | 04/7/2018 |
| Increased expression of the cytoplasmic FMR1-interacting protein 2 (CYFIP2), a known FMRP interactor, is detected in fragile X syndrome. | Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.
Hoeffer CA, Sanchez E, Hagerman RJ, Mu Y, Nguyen DV, Wong H, Whelan AM, Zukin RS, Klann E, Tassone F., Free PMC Article | 09/15/2012 |
| blood samples of lateral sclerosis patients were found to have significantly different levels of expression of CyFIP2 and RbBP9 compared to the levels of expression in control subjects. | Two potential biomarkers identified in mesenchymal stem cells and leukocytes of patients with sporadic amyotrophic lateral sclerosis.
Nachmany H, Wald S, Abekasis M, Bulvik S, Weil M., Free PMC Article | 07/14/2012 |
| Studies identify a novel proapoptotic gene target, CYFIP2, which is downregulated by IMP-1, and mediates the regulation of cell survival and K-Ras expression in colon cancer cells. | IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2.
Mongroo PS, Noubissi FK, Cuatrecasas M, Kalabis J, King CE, Johnstone CN, Bowser MJ, Castells A, Spiegelman VS, Rustgi AK., Free PMC Article | 07/30/2011 |
| Protein complexes containing CYFIP/Sra/PIR121 coordinate Arf1 and Rac1 signalling during clathrin-AP-1-coated carrier biogenesis at the trans-golgi network. | Protein complexes containing CYFIP/Sra/PIR121 coordinate Arf1 and Rac1 signalling during clathrin-AP-1-coated carrier biogenesis at the TGN.
Anitei M, Stange C, Parshina I, Baust T, Schenck A, Raposo G, Kirchhausen T, Hoflack B., Free PMC Article | 05/3/2010 |
| Observational study and genome-wide association study of gene-disease association. (HuGE Navigator) | Evaluation of candidate genes in a genome-wide association study of childhood asthma in Mexicans.
Wu H, Romieu I, Shi M, Hancock DB, Li H, Sienra-Monge JJ, Chiu GY, Xu H, del Rio-Navarro BE, London SJ., Free PMC Article | 12/2/2009 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (2) articlesAnalyses of associations between three positionally cloned asthma candidate genes and asthma or asthma-related phenotypes in a Chinese population.
Zhou H, Hong X, Jiang S, Dong H, Xu X, Xu X. Analyses of associations with asthma in four asthma population samples from Canada and Australia.
Daley D, Lemire M, Akhabir L, Chan-Yeung M, He JQ, McDonald T, Sandford A, Stefanowicz D, Tripp B, Zamar D, Bosse Y, Ferretti V, Montpetit A, Tessier MC, Becker A, Kozyrskyj AL, Beilby J, McCaskie PA, Musk B, Warrington N, James A, Laprise C, Palmer LJ, Paré PD, Hudson TJ. | 03/25/2009 |
| The CYFIP2 promoter contains a p53-responsive element that confers p53 binding as well as transcriptional activation of a heterologous reporter. | CYFIP2, a direct p53 target, is leptomycin-B sensitive.
Jackson RS 2nd, Cho YJ, Stein S, Liang P. | 01/21/2010 |